Suppr超能文献

用于评估骨关节炎膝关节疼痛镇痛起效的步行模型。

A walking model to assess the onset of analgesia in osteoarthritis knee pain.

机构信息

Clinical Research, Merck Research Laboratories, Rahway, NJ 07065, United States.

出版信息

Osteoarthritis Cartilage. 2010 May;18(5):646-53. doi: 10.1016/j.joca.2009.12.008. Epub 2010 Feb 6.

Abstract

OBJECTIVE

To assess a walking model utilizing a set of standardized treadmill walks to measure acute analgesic response in osteoarthritis (OA) of the knee.

DESIGN

Randomized, double-blind, placebo-controlled, multiple dose, three-period crossover study. Patients > or =45 years of age (N=22) with symptomatic knee OA were randomized to naproxen 500 mg bid, tramadol/acetaminophen 37.5 mg/325 mg in forced titration, or placebo in each of three periods. Patients performed multiple 20-minute treadmill walks on Day 1 and Day 3 at a consistent self-selected pace predetermined at screening. Pain intensity (PI) during the walks was assessed on an 11-point numerical rating scale at 0, 3, 6, 9, 12, 15, 18, and 20 min. The primary endpoint was the time-weighted average (TWA) change from baseline PI on Day 3 for the two self-paced walks for the active treatments vs placebo. Time to moderate pain (TTMP) was a key secondary endpoint.

RESULTS

Compared with placebo, the TWA change from baseline PI on Day 3 was significantly better with tramadol/acetaminophen (P=0.043) but not with naproxen (P=0.089). TWA change from baseline on Day 1 was also significantly better with both tramadol/acetaminophen (P=0.001) and naproxen (P=0.048) compared with placebo. TTMP was significantly better for tramadol/acetaminophen and naproxen than placebo (P<0.001 to P=0.015) for walks on Day 1 after a single dose and on Day 3.

CONCLUSIONS

This novel OA pain model was able to discriminate both tramadol/acetaminophen and naproxen from placebo after single and multiple doses. ClinicalTrials.gov identifier: NCT00772967.

摘要

目的

评估一种步行模型,利用一组标准化跑步机行走来测量膝骨关节炎(OA)的急性镇痛反应。

设计

随机、双盲、安慰剂对照、多剂量、三周期交叉研究。>或=45 岁(N=22)有症状膝骨关节炎的患者随机分为萘普生 500mg bid、曲马多/对乙酰氨基酚 37.5mg/325mg 强制滴定或安慰剂,在三个周期中的每个周期中。患者在第 1 天和第 3 天进行多次 20 分钟的跑步机行走,以在筛选时预先确定的一致自我选择速度进行。行走期间的疼痛强度(PI)在 0、3、6、9、12、15、18 和 20 分钟时使用 11 点数字评分量表进行评估。主要终点是与安慰剂相比,第 3 天两次自我 paced 行走的 TWA 从基线 PI 的变化。中度疼痛时间(TTMP)是关键次要终点。

结果

与安慰剂相比,曲马多/对乙酰氨基酚(P=0.043)而非萘普生(P=0.089)在第 3 天从基线 PI 的 TWA 变化明显更好。与安慰剂相比,第 1 天的 TWA 从基线的变化也明显更好,无论是曲马多/对乙酰氨基酚(P=0.001)还是萘普生(P=0.048)。与安慰剂相比,曲马多/对乙酰氨基酚和萘普生在单次和多次剂量后第 1 天和第 3 天的行走时 TTMP 均显著更好(P<0.001 至 P=0.015)。

结论

这种新型 OA 疼痛模型能够在单次和多次剂量后区分曲马多/对乙酰氨基酚和萘普生与安慰剂。ClinicalTrials.gov 标识符:NCT00772967。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验